BioTechnique is a clinical-stage oncolytics company that is focused on discovering and developing novel therapies to treat patients with cancer. Using a next generation nanotechnology drug delivery platform, the company is developing therapies designed to reduce adverse effects associated with traditional chemotherapies and provide a targeted delivery to the tumor location. We are now raising capital to allow us to expand. We are welcoming accredited investors for our second private placement. Our private placement is being managed by Victor Cuilic of Uplift Partners at firstname.lastname@example.org. Please contact our CEO, Mr. John Clapham, for more details regarding this private placement at +1 (626) 786-7035, or jclapham@BioTechnique.com. All private placements shall comply with the US Securities Exchange Commission (SEC) regulations.